← Back to headlines
Pediatrix Reaffirms 2026 Adjusted EBITDA Outlook and Develops Telehybrid Medicine Platform
Pediatrix has reaffirmed its 2026 adjusted EBITDA outlook of $280 million to $300 million, while also focusing on building a telehybrid medicine platform.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
